The only blood test to rule out “silent” kidney rejection
TruGraf®, the First and Only Non-Invasive Tool Validated and Covered by CMS as an Alternative to Surveillance Biopsies to rule out Silent Subclinical Rejection in Patients with Stable Graft Function
~35% of patients receive a surveillance biopsy in the first year
≥75% of patients who have surveillance biopsies show normal histology and the vast majority could have been spared an invasive procedure if tested with TruGraf®
≥20% of patients show subclinical acute rejection